Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIM: Subcutaneous vs Intravenous Morphine in Palliative Cancer Patients
NCT05236647Phase 3Completed
- Start
- Mar 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of morphine in cancer pain (2 arms). Primary endpoint: Time from initiation of i.v./s.c. morphine to stable infusion rate is reached at 48 hours. Started Mar 2022; status: completed.
02
Drugs
morphine
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT05236647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236647.